30results about How to "Recovery quantity" patented technology

The invention discloses an eye drop for treating dry eye, the pH is 5.0-7.0, and its active ingredient is 5-hydroxyl-1-beta-D-furanosyl-1H-imidazole-5-carboxamide, specifically It has the following composition by weight and volume percentage: 5-hydroxyl-1-beta-D-furanosyl-1H-imidazole-5-carboxamide 0.05-0.1%, an appropriate amount of pH regulator, and isotonic agent 0.01-3% , bacteriostat 0.003-0.5%, stabilizer 0.001-0.5%, thickener 0.01-0.5%, solubilizer 2-5%, and the balance is water. The local treatment of the eye drops of the invention can protect the corneal epithelial barrier function of dry eye mice, restore the number of conjunctival goblet cells, and have good anti-inflammatory and immunosuppressive effects.

The invention discloses an application of a brassica napus BnaSPT3 gene in promoting growth of pods of dicotyledons. A base sequence of the brassica napus BnaSPT3 gene is shown as SEQ ID NO.1. The application comprises the following steps: (1) linking the brassica napus BnaSPT3 gene into a plant expression vector, so that a recombinant expression vector is constructed; and (2) transforming the recombinant expression vector into a recipient plant. The invention also discloses the recombinant expression vector containing the brassica napus BnaSPT3 gene and a transformant containing the recombinant expression vector. According to the application provided by the invention, by cloning the brassica napus BnaSPT3 gene, implementing genetic transformation in arabidopsis thaliana and through excessive expression of the exogenous brassica napus BnaSPT3 gene, the size of arabidopsis thaliana spt mutant pods can be obviously increased, and the number of seeds can be recovered. On the basis of genetic engineering technology, over-expression of the brassica napus BnaSPT3 gene in a receptor is achieved, and the size of the pods is changed; therefore, the invention is conducive to high-yield researches.

The invention discloses an oligomeric guluronic acid phosphate as well as a preparation method and an application thereof. The molecular framework of oligomeric guluronic acid phosphate is a linear polymer of L-guluronic acid connected through alpha-(1,4)-glucosidic bonds, in the formula, R1 is pharmaceutical salt such as H, Li, Na, K, Ca or Mg, R2 is H or PO3<2->, the salting mode of -PO32- is accordant with that when R1 is taken as a substituent group, and n is less than or equal to 20. By adopting the oligomeric guluronic acid phosphate, the situation of low immunity of mice caused by cyclophosphamide can be alleviated, the major performance includes that the immune viscera / weight ratio can be increased, the humoral immunity and the cell immunity can be improved, the phagocytic ability of monocyte macrophages is improved, and the numbers of leukocytes and lymphocytes in peripheral hemogram can be remarkably increased. The pharmacology experiment result shows that the oligomeric guluronic acid phosphate disclosed by the invention can be used for preparing medicines, food or functional products with immunological enhancement.

The invention discloses the application of the hepcidin antagonist LDN193189 and its derivatives in the preparation of medicines, belongs to the field of medical technology, and provides the application of the hepcidin antagonist LDN193189 and its derivatives in the preparation and treatment of bone marrow type acute radiation sickness and radiotherapy-induced blood cell drop New uses of applications in disease medicine. Intraperitoneal injection of lethal doses of irradiated mice with LDN193189 and its derivatives can increase the survival rate of irradiated mice to 40% (120 days), and the number of peripheral blood leukocytes and lymphocytes increased significantly; The number of cells was significantly restored; the survival rate of splenic lymphocytes was significantly restored; the number of splenic lymphocytes was significantly increased (HE section). LDN193189 and its derivatives have a good effect on the treatment of bone marrow type acute radiation sickness and radiotherapy-induced cytopenia.